{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:35:36Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 17.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952e-9d02-7b00-9113-c8465caef170\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: isepamicin\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 81.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0952e-9d13-7df0-873f-0309a06564e2\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: isepamicin\nRegistry id: vr.tr.isepamicin\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:42+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:31+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q554818", "registryId": "vr.tr.isepamicin", "name": "isepamicin", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q554818/", "model": { "registry_id": "vr.tr.isepamicin", "name": "isepamicin", "purpose": "Enable an agent to identify isepamicin, assess the condition and suitability of a material containing it, and determine which handling or use decisions require further evidence.", "definition": "Isepamicin is a semisynthetic aminoglycoside antibiotic derived from gentamicin B that inhibits bacterial protein synthesis through interaction with the 30S ribosomal subunit.", "scope_statement": "This model owns the substance identity of isepamicin under vr.tr.isepamicin in PHY / PHY.MAT, including the relationship between its active moiety and supplied chemical forms, material quality, condition-dependent properties, antibacterial evidence, and applicable handling constraints.", "in_scope": [ "Molecular identity, stereochemistry, synonyms, and form-specific identifiers", "Free-base equivalents, salt composition, hydration, assay, and impurities", "Physical state, solubility, stability, and storage history of identified material", "Isepamicin-specific antibacterial activity and resistance evidence", "Material hazards, grade restrictions, and jurisdiction-specific substance requirements" ], "out_of_scope": [ "Finished injectable products, excipients, packaging designs, and product authorization dossiers", "Patient-specific prescribing, dose selection, and therapeutic monitoring decisions", "Manufacturing processes and production equipment", "Complete models of gentamicin, amikacin, other antibiotics, or bacterial organisms", "Institutional antimicrobial stewardship and waste-treatment operations" ], "distinguishing_features": [ "Match the full stereochemical structure to isepamicin rather than identifying it from aminoglycoside class membership or antibacterial activity alone.", "Check the neutral-parent formula C22H43N5O12 and PubChem CID 3037209 against the claimed identity; formula alone cannot establish stereochemistry. [PubChem isepamicin](https://pubchem.ncbi.nlm.nih.gov/compound/3037209)", "Distinguish parent isepamicin from supplied isepamicin sulfate: PubChem assigns the sulfate a separate compound record, CID 636375. [PubChem isepamicin sulfate](https://pubchem.ncbi.nlm.nih.gov/compound/Isepamicin-Sulfate)", "Resolve isepamicin from gentamicin B and related substances analytically; a pharmacopoeial monograph describes isepamicin sulfate as the sulfate of a gentamicin B derivative. [Japanese Pharmacopoeia XVI](https://www.pmda.go.jp/files/000203131.pdf)", "Establish whether a record describes the active substance, a reference standard, or a finished medicine before transferring any identity, purity, or use claim." ], "characteristics": [ { "name": "Chemical form and stereochemical identity", "kind": "category", "unit_or_values": "Verified stereochemical structure; parent, sulfate, other documented form, or unresolved", "why_it_matters": "Prevents confusion with related aminoglycosides and inappropriate transfer of properties between chemical forms." }, { "name": "Identifier assignment", "kind": "relation", "unit_or_values": "Registry id, CAS number, PubChem CID, InChIKey, and EC number where verified, each linked to its chemical form and source", "why_it_matters": "Names alone do not establish whether a document concerns the parent molecule or a salt." }, { "name": "Isepamicin content", "kind": "measurement", "unit_or_values": "mg isepamicin equivalent/g material or mg/mL; state as-is, dried, or anhydrous basis", "why_it_matters": "Allows valid quantity comparisons without equating salt mass with active-moiety mass." }, { "name": "Related-substance profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in validated mass fraction or method-specific area percent", "why_it_matters": "Separates confirmed isepamicin from precursor residues, related aminoglycosides, and degradation products." }, { "name": "Water and counterion content", "kind": "measurement", "unit_or_values": "Water in % w/w; sulfate content or counterion-to-isepamicin molar ratio", "why_it_matters": "Supports material identification and defensible assay corrections." }, { "name": "Physical and solution state", "kind": "state", "unit_or_values": "Solid or solution; appearance, solvent, concentration, pH, and temperature", "why_it_matters": "Makes solubility and stability observations interpretable for the actual material." }, { "name": "Condition-dependent physical properties", "kind": "measurement", "unit_or_values": "Solubility in mg/mL; thermal events in °C with method, pressure, and decomposition status", "why_it_matters": "Prevents assigning unsupported universal melting, boiling, or solubility values." }, { "name": "Antibacterial activity", "kind": "measurement", "unit_or_values": "MIC in mg/L or validated biological potency, linked to organism, strain, method, and conditions", "why_it_matters": "Antibiotic class membership does not establish activity against a particular isolate." }, { "name": "Material qualification", "kind": "state", "unit_or_values": "Reference standard, research grade, qualified pharmaceutical material, quarantined, rejected, or unverified", "why_it_matters": "A chemical identity match does not establish suitability for a particular use." }, { "name": "Handling and legal status", "kind": "relation", "unit_or_values": "Applicable SDS, hazard classification, exposure limit if established, and jurisdiction-specific requirements with dates", "why_it_matters": "Handling and permitted use depend on documented form, grade, location, and current requirements." } ], "affordances": [ "Reconcile an isepamicin label, structure record, and analytical identity result while flagging unresolved salt or stereochemical differences.", "Calculate active-moiety equivalents when assay, water content, counterion composition, and reporting basis are established.", "Compare a material lot with an applicable isepamicin specification and flag failed or missing evidence.", "Assess whether storage or solution conditions remain within a documented stability envelope.", "Compare antibacterial results only after reconciling organisms, assay methods, units, and interpretation criteria.", "Route handling, disposal, or proposed use to the applicable substance guidance and linked product or clinical model." ], "agent_conduct": { "may": [ "Describe isepamicin, its class and approved uses from official drug information.", "Report prescribing information and warnings from regulatory labelling.", "Track stock and expiry in a pharmacy the agent is authorized to manage." ], "must_not": [ "Recommend, dose or adjust isepamicin for a particular patient.", "Downplay its risks of kidney and hearing damage.", "Help anyone obtain it without a prescription.", "Encourage antibiotic use where it is not needed." ], "requires_human": [ "Any prescribing, dosing or monitoring decision for a patient." ] }, "ethics": { "considerations": [ "Aminoglycosides can cause permanent deafness and kidney injury, so careful use matters.", "Overuse of antibiotics drives resistance that harms everyone." ], "affected_parties": [ "Patients", "Prescribers and pharmacists", "The public facing resistant infections" ] }, "owners": { "steward": "The prescribing clinician answers for each use; medicines regulators authorize the product.", "master_systems": [ "National medicines registers" ] }, "failure_modes_and_hazards": [ "Can cause hearing loss, balance problems and kidney damage.", "Misuse contributes to antibiotic resistance." ], "what_it_is_for": [ "Isepamicin occurs in pharmaceutical materials, analytical reference samples and antibacterial research.", "Its medicinal use concerns susceptible bacterial infections, with suitability dependent on the authorized product and clinical assessment." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology classifies isepamicin among aminoglycoside antibacterials." ], "visual_identification": [ "A label naming isepamicin and specifying its chemical form distinguishes a declared sample from other antibiotic materials.", "A batch identifier and matching certificate of analysis support traceability but do not independently prove chemical identity.", "Powder or solution appearance is not specific enough to distinguish isepamicin from other pharmaceutical substances." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q554818: isepamicin", "url": "https://www.wikidata.org/wiki/Q554818", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Isepamicin", "url": "https://en.wikipedia.org/wiki/Isepamicin", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "isepamicin-identity", "name": "Isepamicin identity", "description": "Establish which molecular entity and supplied form a record or sample represents.", "rationale": "Related aminoglycosides and isepamicin salts must remain distinguishable while referring to one registered substance concept.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Recognize isepamicin through structure and analytical evidence.", "findings": [ { "id": "stereochemical-match", "name": "Stereochemical match", "description": "Require evidence that distinguishes isepamicin from related aminoglycosides and stereochemical alternatives.", "questions": [ { "text": "Which verified structure, including stereochemistry, defines isepamicin for this record?", "kind": "definition", "id": "stereochemical-match-q01" }, { "text": "Which reference-standard comparison or orthogonal analytical results establish that the sample is isepamicin?", "kind": "measurement", "id": "stereochemical-match-q02" } ] } ] }, { "id": "parent-and-salt", "name": "Parent and salt", "description": "Relate supplied forms and identifiers to the isepamicin active moiety.", "findings": [ { "id": "form-specific-identity", "name": "Form-specific identity", "description": "Keep parent, sulfate, hydration, and formulation information explicit without creating an unsupported registry split.", "questions": [ { "text": "Does the material contain parent isepamicin, a characterized sulfate, or another documented form?", "kind": "boundary", "id": "form-specific-identity-q01" }, { "text": "Which authoritative records assign each CAS number, CID, or other identifier to that exact form?", "kind": "provenance", "id": "form-specific-identity-q02" } ] } ] } ] }, { "id": "isepamicin-content-and-quality", "name": "Isepamicin content and quality", "description": "Determine how much isepamicin a material contains and whether its impurity profile supports the intended use.", "rationale": "Salt mass, analytical purity, and biological potency answer different questions about usable material.", "layers": [ { "id": "content-basis", "name": "Content basis", "description": "Make isepamicin quantities comparable across solids, salts, and solutions.", "findings": [ { "id": "active-moiety-accounting", "name": "Active-moiety accounting", "description": "Tie reported content to assay method, reference standard, and water or counterion corrections.", "questions": [ { "text": "Is the reported quantity salt mass, parent-isepamicin equivalent, or biological potency?", "kind": "definition", "id": "active-moiety-accounting-q01" }, { "text": "What measured assay, water content, and counterion composition support conversion to isepamicin equivalents?", "kind": "measurement", "id": "active-moiety-accounting-q02" } ] } ] }, { "id": "related-substances-and-grade", "name": "Related substances and grade", "description": "Evaluate precursor residues, related aminoglycosides, degradation products, and applicable material specifications.", "findings": [ { "id": "quality-evidence", "name": "Quality evidence", "description": "Qualify the material using a traceable specification rather than a purity claim alone.", "questions": [ { "text": "Which method resolves isepamicin from gentamicin B and other relevant related substances, and what limits apply?", "kind": "measurement", "id": "quality-evidence-q01" }, { "text": "Which specification and certificate establish the material's grade, and which failed or absent tests require quarantine?", "kind": "action", "id": "quality-evidence-q02" } ] } ] } ] }, { "id": "isepamicin-material-condition", "name": "Isepamicin material condition", "description": "Connect physical properties and stability evidence to the actual isepamicin form and its history.", "rationale": "Properties of a sulfate solid or prepared solution cannot automatically describe every isepamicin material.", "layers": [ { "id": "phase-and-solution-properties", "name": "Phase and solution properties", "description": "Record properties under specified solvent, pH, temperature, and pressure conditions.", "findings": [ { "id": "conditional-property-record", "name": "Conditional property record", "description": "Distinguish measured equilibrium properties from preparation observations or decomposition events.", "questions": [ { "text": "What chemical form, solvent, pH, temperature, and method accompany each reported solubility value?", "kind": "measurement", "id": "conditional-property-record-q01" }, { "text": "Do reported thermal values represent melting, water loss, or decomposition, and is a boiling point actually established?", "kind": "measurement", "id": "conditional-property-record-q02" } ] } ] }, { "id": "storage-and-degradation", "name": "Storage and degradation", "description": "Assess material history against evidence for retained isepamicin content and quality.", "findings": [ { "id": "stability-envelope", "name": "Stability envelope", "description": "Apply stability claims only to supported forms, concentrations, containers, and environmental conditions.", "questions": [ { "text": "Which studies establish acceptable storage and solution hold conditions for this isepamicin material?", "kind": "provenance", "id": "stability-envelope-q01" }, { "text": "After an excursion or solution preparation, which assay and degradation results are needed before continued use?", "kind": "action", "id": "stability-envelope-q02" } ] } ] } ] }, { "id": "isepamicin-antibacterial-evidence", "name": "Isepamicin antibacterial evidence", "description": "Represent measured antibacterial activity and the limits imposed by test conditions and resistance.", "rationale": "An agent needs isepamicin-specific evidence before interpreting activity or extrapolating from another aminoglycoside.", "layers": [ { "id": "activity-measurement", "name": "Activity measurement", "description": "Bind antibacterial observations to the tested material and organism.", "findings": [ { "id": "traceable-activity-result", "name": "Traceable activity result", "description": "Keep potency assays and isolate susceptibility measurements distinct and reproducible.", "questions": [ { "text": "Which organism or isolate, medium, inoculum, incubation conditions, and isepamicin concentration basis produced the result?", "kind": "measurement", "id": "traceable-activity-result-q01" }, { "text": "Does the result quantify material potency, organism susceptibility, or another experimental endpoint?", "kind": "boundary", "id": "traceable-activity-result-q02" } ] } ] }, { "id": "resistance-and-interpretation", "name": "Resistance and interpretation", "description": "Constrain extrapolation from resistance mechanisms and interpretive standards.", "findings": [ { "id": "supported-susceptibility-inference", "name": "Supported susceptibility inference", "description": "Require direct support for isepamicin resistance claims and categorical susceptibility interpretations.", "questions": [ { "text": "Which isepamicin-specific experiments support the effect of each reported resistance mechanism?", "kind": "provenance", "id": "supported-susceptibility-inference-q01" }, { "text": "Is a current isepamicin breakpoint applicable to this organism and method, or must the result remain an uninterpreted MIC?", "kind": "boundary", "id": "supported-susceptibility-inference-q02" } ] } ] } ] }, { "id": "isepamicin-use-constraints", "name": "Isepamicin use constraints", "description": "Connect material hazards and qualification evidence to permissible handling and downstream use.", "rationale": "Substance identity and antibacterial activity alone do not establish safe handling or authorization for medicinal use.", "layers": [ { "id": "exposure-and-disposal", "name": "Exposure and disposal", "description": "Resolve handling requirements for the supplied isepamicin form and concentration.", "findings": [ { "id": "documented-hazard-controls", "name": "Documented hazard controls", "description": "Base exposure and waste decisions on applicable evidence, preserving unknown classifications or limits.", "questions": [ { "text": "Which current SDS or authoritative assessment supports the hazard classification and any exposure limit for this form?", "kind": "provenance", "id": "documented-hazard-controls-q01" }, { "text": "Which documented controls apply to weighing, solution handling, spills, and disposal of this antibacterial material?", "kind": "action", "id": "documented-hazard-controls-q02" } ] } ] }, { "id": "qualification-and-jurisdiction", "name": "Qualification and jurisdiction", "description": "Separate substance qualification from finished-product authorization and patient decisions.", "findings": [ { "id": "permitted-use-evidence", "name": "Permitted-use evidence", "description": "Require current, jurisdiction-specific evidence for the proposed material use.", "questions": [ { "text": "Which current monograph, supplier qualification, or regulatory record governs this isepamicin material in the relevant jurisdiction?", "kind": "provenance", "id": "permitted-use-evidence-q01" }, { "text": "Does the proposed action require a linked finished-product or clinical model before it can be authorized?", "kind": "boundary", "id": "permitted-use-evidence-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled knowledge, with no sources consulted.", "Verify exact registry identifiers, salt stoichiometry and physical constants before assigning them to a material record.", "Check current national product information for authorization, formulation and approved uses." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Isepamicin free base", "Isepamicin sulfate" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "isepamicin", "note": "Names the active substance; salt and formulation should be specified separately." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Parenteral treatment of infections caused by susceptible bacteria, particularly aerobic Gram-negative organisms.", "Laboratory antimicrobial susceptibility testing and studies of aminoglycoside resistance." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Nephrotoxicity.", "Ototoxicity, potentially affecting hearing or balance.", "Neuromuscular blockade.", "Accumulation when renal clearance is impaired.", "Antibacterial treatment failure caused by resistance; stability against some aminoglycoside-modifying enzymes does not confer universal protection." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Marketing authorization, availability and approved indications differ between countries." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Gentamicin B", "difference": "Isepamicin is a chemically modified derivative of gentamicin B, bearing an additional aminohydroxypropionyl side chain." }, { "name": "Amikacin", "difference": "Amikacin is derived from kanamycin A and has a different side chain and parent aminoglycoside structure." }, { "name": "Isepamicin sulfate", "difference": "The sulfate is a salt form; its composition and formula mass must include the counterion rather than describe only the parent substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of isepamicin this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative stereochemical record and form-specific CAS and EC assignments should anchor this registry entry, including documented sulfate composition and hydration variability?", "Which current pharmacopoeial specifications and validated methods govern isepamicin assay, biological potency, gentamicin B residues, and other related substances?", "Which measured solubility, thermal behavior, degradation pathways, and storage limits are established separately for parent isepamicin, sulfate material, and solutions?", "Which current isepamicin-specific susceptibility breakpoints and experimentally demonstrated resistance mechanisms support interpretation without extrapolating from other aminoglycosides?", "Which current jurisdiction-specific substance requirements, SDS classifications, exposure limits if any, and toxicological evidence govern handling and the boundary with medicinal use?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 27 } }